Back to Stocks
Rank #1722VXRT
Vaxart, Inc.
$0.55
0.93% (Daily)
Market Cap
$130.83M
Revenue
$148.20M
Rank by MCap
#1722
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Steven Lo
Headquarters
South San Francisco, CA
Employees
105
About Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal in...
Vaxart, Inc. Price Chart
Loading chart…